Total
0
Shares
Jatcorp (ASX:JAT) - Managing Director, Wilton Yao (centre)
Managing Director, Wilton Yao (centre)
Source: Jatcorp
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Health and wellness consumer goods developer Jatenergy (JAT) has teamed up with the University of Sydney to develop an antiviral food supplement
  • The formula will aim to prevent common infectious diseases such as influenza, herpes simplex virus and norovirus
  • Jatenergy says the food supplement will be based on lactoferrin, a glycoprotein which helps limit and kill bacteria, viruses and parasites
  • The research is expected to be completed by April 2021 and aims to be on the Australian market by early 2022
  • JAT is up 11.8 per cent on the market this morning and is selling shares for 3.8¢ apiece

Health and wellness consumer goods developer Jatenergy (JAT) has teamed up with the University of Sydney to develop an antiviral food supplement.

The company and the university’s brainchild is expected to include antiviral properties that work against a broad range of pathogens.

The formula will aim to help prevent common infectious diseases such as influenza, herpes simplex virus and norovirus. The food supplement will be based on lactoferrin, a glycoprotein which can limit and kill bacteria, viruses and parasites.

Roles of the agreement

Under the agreement, JAT will provide management support and general assistance to the University’s research team. The company will also provide lactoferrin and lactoferrin-based products for testing.

The University of Sydney will be undertaking the necessary testing.

“We look forward to harnessing University of Sydney‘s formidable research capabilities as we jointly research and develop foods of the future which could help to mitigate future viral outbreaks,” said Jatenergy Managing Director Wilton Yao.

Outcomes

The research is expected to be completed by April 2021. JAT will work with the University to ensure that the compounds, which are developed through the research, are registered with the Australian Therapeutic Goods Administration (TGA).

The TGA will allow for marketing in Australia, which is expected to be in late 2021 or early 2022.

JAT is up 11.8 per cent on the market this morning and is selling shares for 3.8¢ apiece at 12:13 pm AEDT.

JAT by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.